Please login to the form below

Not currently logged in
Email:
Password:

F2G appoints chief financial officer

Ralf Schmid brings experience from Nabriva Therapeutics

F2G Ralf SchmidManchester-based F2G Ltd has appointed Ralf Schmid as its new chief financial officer.

Schmid brings over two decades of financial management experience to the antifungal drug discovery and development company, with particular expertise in mergers and acquisitions, licensing and public and private market transactions.

He moves to F2G from Nabriva Therapeutics, where he had been a member of the management board since the Austrian biopharmaceutical company's inception in 2006.

Schmid first served as the firm's chief financial officer, before becoming chief executive officer, and most recently held the dual post of chief operating officer and chief financial officer.

 Ian Nicholson, chief executive of F2G, said: “Following our successful $60m financing, I am delighted to welcome Ralf to the F2G team.

“His strong track record in fundraising, M&A transactions and deal structuring will be invaluable as we continue to generate positive data from our clinical trials and position the company for success.”

14th July 2016

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

digital launch
How can virtual pharma companies de-risk new product launches?
The risks and challenges involved in taking specialty drugs, biopharmaceuticals and drug/device combinations to market...
Not waving but drowning. Reflections on data curation in the age of information overload
...
digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...

Infographics